Neurogastrx, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neurogastrx.com
Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist
Phase 2
Active, not recruiting
- Conditions
- Overweight and ObesityHealthy
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Neurogastrx, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06500429
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
Phase 2
Completed
- Conditions
- Diabetic GastroparesisIdiopathic Gastroparesis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Neurogastrx, Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT04303195
- Locations
- 🇺🇸
Digestive Health Specialists, Dothan, Alabama, United States
🇺🇸G & L Research, LLC, Foley, Alabama, United States
🇺🇸East View Medical Research, Mobile, Alabama, United States
News
No news found